Powervision company presentation from OIS@AAO 2014

1. Company Presentation
October 16, 2014

2. Overview
• No change to the surgical procedure
• Performance proven in clinical studies
• Strong IP position
• Multi-billion dollar market potential
• Experienced management team
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
• Proprietary FluidVision™ accommodating intraocular lens
(A-IOL)
• Only technology that restores “true accommodation”

3. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Key Feature What it Means
Give Patients the
Ability to See Near,
Far and Anywhere in
Between
• Distance acuity 20/20 or better
• 2.5 diopters of accommodation – can see well at near
(40 cm/16 inches)
• Continuously variable between near and distance
Maintain the Natural
Mechanism of
Accommodation
• Shape change
• Intracapsular vs. sulcus fixated
• Ciliary muscle-powered
• “Forward” accommodation
Restoration of True Accommodation™

4. The PowerVision Approach
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
• Efficiently harness natural muscular forces
in the eye to move fluids inside the lens
• Translate that fluid movement into a shape
change, which leads to a large change in
power
• Shape change is many times more “optically
efficient” than designs with a shifting/
vaulting lens
• Maintains the natural mechanism of
accommodation
• Restores True Accommodation™
To see the FluidVision lens in action, visit www.powervisionlens.com

5. • When the eye moves to its natural
accommodated state, the capsular
bag, which now contains our IOL,
squeezes a tiny amount of fluid
from the haptics at the periphery
of our IOL into the center
• This inflates our lens, giving near
vision
• When the eye attempts to move
to its dis-accommodated state,
the capsular bag squeezes fluid
the other way
• This deflates our lens, giving far
vision
How the FluidVision Lens Works
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
ACCOMMODATED
STATE
(NEAR VISION)
DISACCOMMODATED
STATE
(FAR VISION)
CAPSULAR BAG

6. PowerJect Delivery System
• The FluidVision lens is paired with the novel PowerJect™
“injector”
• The injector utilizes a unique fluid-based method of
delivering the lens into the capsular bag
• No change to the surgical procedure
• Lens comes pre-loaded for ease of use
INJECTOR
PRE-LOADED LENS WITH CARTRIDGE
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE

7. Summary of Clinical Studies
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Study Purpose Device N Key Results
Blind Eyes
(monocular) Single
Center
Completed 2008
Demonstrate lens
movement under
drug stimulation
Non-Optical,
Non-Injectable
5
• Showed significant movement equivalent to
desired accommodation
Sighted Eyes
(monocular) Single
Center
Completed 2011
Demonstrate optical
performance in vivo
and accommodation
Optical,
Non-Injectable
13
• Showed good visual performance and desired
accommodation
• Demonstrated stability out to 1 year
Sighted Eyes
(monocular) Single
Center Pilot
Enrollment Completed 2013
Demonstrate
accommodation and
injectability
Optical,
Injectable
20
• Showed injectability
• Showed excellent distance (20/20) and
intermediate visual acuity
• Showed excellent near visual acuity (~20/25
expected binocular)
• Showed desired accommodation
See detailed slides
Sighted Eyes
(monocular/
binocular)
Multi Center
Ongoing
Support CE Mark
Approval
Optical,
Injectable
115 Early results consistent with pilot study
= Currently Enrolling

8. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Twelve Month Clinical Results – Pilot Study
Nichamin, LD, Clinical Investigation Status of a Novel Fluid Filled Hydrophobic Acrylic Accommodative Intraocular Lens. Presented at: XXXII Congress of the European Society
of Cataract and Refractive Surgeons; 13-17 September 2014; London, United Kingdom
-0.20
-0.10
0.00
0.10
0.20
0.30
0.40
0.50
Month 1 Month 3 Month 6 Month 12
VisualAcuity,logMAR
Follow-up Period
BCDA

9. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Twelve Month Clinical Results – Pilot Study
Nichamin, LD, Clinical Investigation Status of a Novel Fluid Filled Hydrophobic Acrylic Accommodative Intraocular Lens. Presented at: XXXII Congress of the European Society
of Cataract and Refractive Surgeons; 13-17 September 2014; London, United Kingdom
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
Month 1 Month3 Month 6 Month 12
DefocusRange,D
Follow-up Period
Defocus Range (>0.3 logMAR)
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
1 Month 3 Month 6 Month 12 Month
Accommodation,D
Follow-up Period
Accommodation, Push-down

10. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Twelve Month Clinical Results – Pilot Study
Nichamin, LD, Clinical Investigation Status of a Novel Fluid Filled Hydrophobic Acrylic Accommodative Intraocular Lens. Presented at: XXXII Congress of the European Society
of Cataract and Refractive Surgeons; 13-17 September 2014; London, United Kingdom
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
5.00
1 M 3 M 6 M 12 M
CyclotoPiloAccommodation,D
Follow-up Period
Pilocarpine Induced Accommodation

11. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Twelve Month Clinical Results – Pilot Study
Roux P, Potgieter F, Nichamin, LD, Accommodative Capacity of a Novel Fluid Filled Hydrophobic Acrylic Accommodative Intraocular Lens. Presented at: XXXII Congress of the
European Society of Cataract and Refractive Surgeons; 13-17 September 2014; London, United Kingdom
Mesopic CS
Mesopic CS

12. 3.5 mm incision
Near visual acuity to 20/20
2.8 mm incision
Post implant adjustment
Near Term
Longer Term
Product Development Plans
CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE

13. CONFIDENTIAL – DO NOT DUPLICATE OR DISTRIBUTE
Company Plans
• The Company is more than halfway through enrollment in its
multi-center CE mark trial in South Africa and Germany
• This study is expected to lead to the CE mark next year
• U.S. FDA trials are expected to begin in 2015
• Company recently completed the final tranche of its $30MM Series
D round